Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-237 (Ivermectin) in Mild COVID-19
NCT05056883Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19), sponsored by Kowa Company, Ltd.. Started Oct 2021; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05056883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056883.